Dr Sam M Mbulaiteye
MBChB, MPhil, MMed
Dr. Mbulaiteye is a senior investigator in the Infections and Immunoepidemiology Branch (IIB) in the Division of Cancer Epidemiology and Genetics (DCEG) at the US National Cancer Institute (NCI). He conducts multidisciplinary epidemiological research to understand the role of infections, immunity, and genetic factors in the aetiology of cancer, particularly Burkitt lymphoma and Kaposi sarcoma.
To achieve these goals, Dr. Mbulaiteye designed and conducted a large multi-country, multiyear case-control study of endemic Burkitt lymphoma called ( ) in six rural regions in Uganda, Tanzania, and Kenya between 2010-2016. EMBLEM collected well annotated samples to facilitate research for the discovery of biomarkers that may be used for early detection, diagnosis, prognosis, or prevention of Burkitt lymphoma.
In addition, Dr. Mbulaiteye has established collaboration with the AI-REAL study as an investigator, a member of the Steering Committee, and as a mentor. He has provided full access to his collaborators at St. Mary’s Hospital Lacor in Uganda to the AI-REAL study and allowed full collaborative access to the EMBLEM facilities in Uganda.